Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

NCT00195533 · clinicaltrials.gov ↗

COMPLETED

Status

801

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematological Malignancy
Leukemia
Myelodysplasia
Lymphoma
Myeloma
Stem Cell Transplantation

Interventions

DRUG: piperacillin-tazobactam
DRUG: glycopeptide

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Collaborators

[object Object]